CASP3 and neoplasm: Numerous data show decreased cell proliferation and increased caspase-3 activity after the use of mTOR inhibitors in many cases of tumours such as pancreatic (Peng and Dou 2017), breast (Woo et al. 2017), and colon cancer (He et al. 2016).